Reflections on common medication reconciliation practices impacting a case of discounted thyroid replacement hormone

Christopher Trautman, Jed C. Cowdell, Nancy Dawson, Michael Maniaci*

Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA

Received: October 28, 2015 Accepted: December 4, 2015 Online Published: December 10, 2015
DOI: 10.5430/crim.v3n1p29 URL: http://dx.doi.org/10.5430/crim.v3n1p29

ABSTRACT

Quality problem or issue: Medication errors related to reconciliation processes.
Initial assessment: Even though most US medical centers utilize medication reconciliation processes to reduce medical errors, adverse events related to medications continue to occur causing extra burden on the US healthcare system. New strategies to reduce medication errors are being implemented, including pharmacy-based medication reconciliations.
Case report: An 86-year-old female was admitted for symptomatic bradycardia in the setting of a fall. During her hospitalization, she was evaluated for pacemaker implantation until her thyroid-stimulating hormone blood test revealed severe hypothyroidism. Medication reconciliation had been performed twice with the patient, and her family adamantly affirmed the patient was compliant on her levothyroxine. Upon further investigation, she had changed pharmacies nine months prior to her hospitalization and was obtaining her thyroid replacement hormone from an online Canadian pharmacy. Once restarting Synthroid, her symptoms improved allowing her to forego the procedure.
Lessons learned: Physicians must understand common pitfalls with rapidly verifying home medications against electronic medical records as patient knowledge of their home therapies is often inaccurate in combination with non-updated electronic data. Hospitals are evaluating strategies such as pharmacy-based medication reconciliations to reduce adverse events related to medication errors, which can decrease hospital costs and improve patient outcomes. Knowing which pharmacy is dispensing the medications can prove useful as discounted medications from online pharmacies may lack efficacy.

Key Words: Medication reconciliation, Medication errors, Levothyroxine, Drug efficacy

1. INTRODUCTION

Adverse drug events are common and potentially harmful to patients in addition to costing the United States approximately $3.5 billion annually. Most medical centers perform a medication reconciliation to compare all active medications used by the patient with documented medications at time of treatment. This method has been proven to reduce medication errors and endorsed by multiple groups, including the U.S. Joint Commission for Accreditation of Healthcare Organizations and World Health Organization. Unfortunately, medication reconciliations are not accurately obtained for a multitude of reasons, including unfamiliarity by the patient/family regarding medications,
computer errors, polypharmacy, and limited time available to complete a full reconciliation.\textsuperscript{[6]} We present here a case report showing the importance of a complete medication reconciliation and how interventions and management can be impacted by a single medication.

2. CASE PRESENTATION

An 86-year-old female with history of chronic kidney disease, bipolar disorder, hypothyroidism, and hypertension presented to the emergency department after a fall. The patient recalled walking towards the kitchen and feeling unsteady on her feet. She went to reach for a countertop as she recognized she was falling, but was unable to support herself. She landed on a carpeted surface hurting her right knee. She denied head trauma, loss of consciousness, loss of bowel/bladder control, or biting her tongue. Her son detailed several similar falls over the past six months due to lower extremity weakness. She had been seen by neurology, who recommended physical therapy for improved physical conditioning. Associated with her fall, the son detailed increased confusion over the previous 24 hours, stating she was making confused statements. Upon reviewing her medications, no recent adjustments had been made and she was compliant on all of her medications. She continued to take amlodipine for blood pressure, levothyroxine for hypothyroidism, and olanzapine/sertraline for mood stabilization. She noted taking melatonin to sleep at night, but denied any benzodiazepine/antihistamine products. She had no prior history of baseline dementia. Review of systems was positive for intermittent dizziness/unsteadiness, lower extremity weakness, and difficulty sleeping. The patient denied recent illness, fevers, shortness of breath, palpitations, gastrointestinal symptoms, bleeding, skin rashes, tremor, or vertigo.

In the emergency department, the patient was found to be bradycardic with a resting heart rate ranging 45-55 bpm, but otherwise, vital signs were within normal limits. On exam, she was well nourished, alert, and oriented without any distress. Pertinent findings included a grade 2/6 systolic murmur in the aortic region, no carotid bruits, 4/5 lower extremity strength bilaterally, limited range of motion of the right knee due to trauma without swelling, and signs of poor short-term memory as she would repeat questions. Blood pressure was not orthostatic. Her initial laboratory findings showed reduced glomerular filtration rate at baseline, hypomagnesaemia, hypokalemia, and slight anemia. The electrocardiogram (EKG) revealed sinus bradycardia with a 1st degree atrioventricular block with a lengthening PR interval changed from an EKG obtained six months prior. No acute pathology was seen on her chest imaging. Cardiology was consulted to further investigate her bradycardia. Initially, her olanzapine was held due to concerns with improper home dosing and adverse effect of hypotension and syncope. While observing the patient over the weekend, no change was seen in her heart rate and an echocardiogram showed diastolic dysfunction with a preserved ejection fraction. On hospital day three, cardiac electrophysiology was consulted for pacemaker placement given signs of symptomatic bradycardia. Prior to taking the patient into the interventional suite, a pending thyroid-stimulating hormone (TSH) level came back as 98.4 mIU/L (normal 0.30-4.20 mIU/L), indicating severe hypothyroidism. The patient’s previous TSH from one year prior was 4.66 mIU/L, with numerous stable readings evident from preceding years. Subsequent free T4 and total T3 were both found to be low.

Upon reinvestigating the patient’s medication history, both the patient and her son affirmed that she was compliant on her levothyroxine, and the dose had not changed in many years. However, the son mentioned a change in pharmacy for her thyroid hormone supplementation. Approximately 9 months prior, he researched a low-cost online pharmacy based out of Canada dispensing levothyroxine at half the cost of his local pharmacy. Given her newly diagnosed uncontrolled hypothyroidism, she was given IV thyroxine, which facilitated improvement in her heart rate over the next 24-48 hours. She was discharged without cardiac device placement to a short-term rehabilitation facility with follow-up thyroid studies ordered.

3. DISCUSSION

For this case, a medication reconciliation was performed twice, once in the emergency department and repeated upon admission. Both reconciliations accurately reflected the medications being used at home by the patient, yet an error still occurred, causing delay in appropriate management. A full medication reconciliation can take up to twenty minutes in order to obtain a full chart review and medication history interview and facilitate the necessary documentation and interventions.\textsuperscript{[7]} However, most physician performed reconciliations take less than ten minutes as constraints on time limit the ability to investigate all details related to medication history. Furthermore, there is inherent confusion among staff members regarding who should perform the reconciliation. Lee and colleagues paneled attending physicians, resident physicians, pharmacists, and nurses regarding who is responsible for medication history at time of admission. Their study showed an unclear expectation for each paneled group resulting in no clear consensus for accountability of completing the task.\textsuperscript{[8]}

One solution proposed by van dem Bemt and colleagues suggests implementation of pharmacy-based medication rec-
As for this patient's drug discrepancy, several drug classes within a health system. Published by Sciedu Press

To L-thyroxine (LT4) equivalency among competing interests, efficacy. Studied revealing non-equivalence in bioavailability and/or interactions, anticonvulsants, and conjugated estrogens have been drugs for brand name drugs. In particular, thyroid substitutions have been labeled as problematic when substituting generic formulations for brand names. Because of this, multiple societies, including the American Association of Clinical Endocrinologists, The Endocrine Society, and American Thyroid Association, have signed a joint statement recommending physicians educate their patients on monitoring pharmacy substitutions, maintaining the same preparation of LT4, and understanding the necessity of TSH testing when making adjustments to dosing.

Although quickly verifying home medications against electronic medical records seems time efficient and complete, physicians must understand common pitfalls with this method as patient knowledge of their home therapies is often inaccurate in combination with non-updated electronic data. Hospitals are evaluating strategies such as pharmacy-based medication reconciliations to reduce adverse events related to medication errors, which can decrease hospital costs and improve patient outcomes. As seen in this case, knowing which pharmacy is dispensing the medicines can prove useful due to lack of familiarity with drugs or limited experience within a health system.

As for this patient’s drug discrepancy, several drug classes have been labeled as problematic when substituting generic drugs for brand name drugs. In particular, thyroid substitutions, anticonvulsants, and conjugated estrogens have been studied revealing non-equivalence in bioavailability and/or efficacy. Due to a history of confounding evidence related to L-thyroxine (LT4) equivalency among competing interests, the Food and Drug Administration passed legislation in 1997 requiring manufacturers of LT4 to seek new drug approval in order to evaluate performance of each preparation. This addresses the narrow therapeutic window of the drug in addition to looking at shelf-life standardizations; however, a lack of viable evidence still remains related to safety of substituting generic formulations for brand names. Because of this, multiple societies, including the American Association of Clinical Endocrinologists, The Endocrine Society, and American Thyroid Association, have signed a joint statement recommending physicians educate their patients on monitoring pharmacy substitutions, maintaining the same preparation of LT4, and understanding the necessity of TSH testing when making adjustments to dosing.

Although quickly verifying home medications against electronic medical records seems time efficient and complete, physicians must understand common pitfalls with this method as patient knowledge of their home therapies is often inaccurate in combination with non-updated electronic data. Hospitals are evaluating strategies such as pharmacy-based medication reconciliations to reduce adverse events related to medication errors, which can decrease hospital costs and improve patient outcomes. As seen in this case, knowing which pharmacy is dispensing the medicines can prove useful for determining the efficacy of medication. Not all medications are formulated equal, especially as patients are seeking discounted medications from online pharmacies.

**REFERENCES**


